- Home
- ALLO vs HOUS Comparison
ALLO vs HOUS Comparison
Compare ALLO & HOUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- HOUS
- Stock Information
- Founded
- ALLO 2017
- HOUS 2006
- Country
- ALLO United States
- HOUS United States
- Employees
- ALLO N/A
- HOUS N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- HOUS Real Estate
- Sector
- ALLO Health Care
- HOUS Finance
- Exchange
- ALLO Nasdaq
- HOUS Nasdaq
- Market Cap
- ALLO 338.9M
- HOUS 368.3M
- IPO Year
- ALLO 2018
- HOUS 2006
- Fundamental
- Price
- ALLO $1.44
- HOUS $3.51
- Analyst Decision
- ALLO Strong Buy
- HOUS Sell
- Analyst Count
- ALLO 10
- HOUS 1
- Target Price
- ALLO $9.66
- HOUS $3.00
- AVG Volume (30 Days)
- ALLO 3.3M
- HOUS 1.1M
- Earning Date
- ALLO 05-12-2025
- HOUS 04-24-2025
- Dividend Yield
- ALLO N/A
- HOUS N/A
- EPS Growth
- ALLO N/A
- HOUS N/A
- EPS
- ALLO N/A
- HOUS N/A
- Revenue
- ALLO $22,000.00
- HOUS $5,692,000,000.00
- Revenue This Year
- ALLO N/A
- HOUS $5.17
- Revenue Next Year
- ALLO $8.30
- HOUS $5.75
- P/E Ratio
- ALLO N/A
- HOUS N/A
- Revenue Growth
- ALLO N/A
- HOUS 0.99
- 52 Week Low
- ALLO $1.30
- HOUS $2.71
- 52 Week High
- ALLO $4.30
- HOUS $6.19
- Technical
- Relative Strength Index (RSI)
- ALLO 36.16
- HOUS 48.21
- Support Level
- ALLO $1.49
- HOUS $3.28
- Resistance Level
- ALLO $1.69
- HOUS $3.88
- Average True Range (ATR)
- ALLO 0.14
- HOUS 0.21
- MACD
- ALLO -0.03
- HOUS -0.02
- Stochastic Oscillator
- ALLO 17.50
- HOUS 27.71
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
About HOUS Anywhere Real Estate Inc.
Anywhere Real Estate Inc operates in residential real estate, focusing on brokerage, relocation, title, settlement businesses, and mortgage and title insurance ventures. It supports approximately 1 million home sale sides annually. Brands include Better Homes and Gardens, CENTURY 21, Coldwell Banker, Corcoran, ERA, and Sotheby's International Realty. Revenue comes mainly from existing home transactions. Operations are segmented into Anywhere Brands (franchises), Anywhere Advisors (owned brokerage), and Anywhere Integrated Services (title and settlement).